Sotorasib in KRAS-Mutated Colorectal Cancer. Reply

N Engl J Med. 2024 Jul 11;391(2):187. doi: 10.1056/NEJMc2406109.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use
  • Clinical Trials as Topic
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Mutation
  • Panitumumab* / therapeutic use
  • Piperazines
  • Proto-Oncogene Proteins p21(ras)* / genetics
  • Pyridines / therapeutic use
  • Pyrimidines / therapeutic use

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors
  • KRAS protein, human
  • Panitumumab
  • Piperazines
  • Proto-Oncogene Proteins p21(ras)
  • Pyridines
  • Pyrimidines
  • sotorasib